• Wion
  • /World
  • /CureVac enrols first participant in pivotal study of COVID vaccine

CureVac enrols first participant in pivotal study of COVID vaccine

CureVac enrols first participant in pivotal study of COVID vaccine

Covid vaccine

Germany`s CureVac announced on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate.

The trial will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement.


(More details expected)